News
Saisei Pharma plans clinical study of oral MAF in COVID-19 patients details were featured on some website.
Please check the below URL.
This time, the Saisei Mirai, has contracted official partnership with the Ukrainian National Cancer Center as partner hospitals.
Please check the link below.
Third
Generation GcMAF
Saisei Mirai
Saisei Pharma
Tokushima University
Developed by Saisei Mirai and Tokushima University in 2014.
Oral GcMAF
~ MAF Series ~
• GcMAF produced from bovine colostrum.
• 1mg capsule has equivalent activity to 100ng purified GcMAF.
• Enteric acid-resistant capsule for oral administration, powder for sublingual
• Target Payer‘s Patches/GUT and Waldeyer’s tonsillar ring.
• New patents pending production process
• Permitted as a food product in Japan
Second
Generation GcMAF
Developed by Saisei Mirai and the University of Tokushima in 2010.
・High concentration (1500 ng/0.5 ml, 1 dose)
・Significantly higher stability and macrophage activating activity
・Sterilization process using 0.22 μm filtration system
・New patented production process
First
Generation GcMAF
Tokushima University
Dr.Yamamoto
・Low stability at room temperature
・Chemically isolated (purified), sterilization process using 0.22 μm filtration system
・25-(OH) Vitamin D3 Affinity Column
・Affinity column has cross-contamination risk when used repeatedly; must be disposable
Cancer treatments / Skin rejuvenation treatments
Cancer treatments / Immunotherapy
Cancer treatments
Skin Beauty treatments
Saisei Mirai immunotherapy laboratory for the production of GcMAF,
Hyper T/NK cells, lymphocytes and other immunotherapies.
This site is for our patients and medical personnel.
Saisei Pharma is a bio venture company, developing Oral Colostrum GcMAF and researching ultrasonic sensitizers and electric field therapy.
